Your Article Summary
See Latest ArticlesU.S. Army Botulinum Neurotoxin (BoNT) Medical Therapeutics Research Program: past accomplishments and future directions
Drug Development Research, 06/19/09
Larsen JC et al. - The development of small molecules for the treatment of BoNT has also been supported. Efforts have focused on molecules to inhibit nearly every aspect of BoNT pathogenesis. This would include toxin binding, translocation, catalytic activity, and recovery following intoxication. Several compounds capable of inhibiting toxin activity or mitigating the severity of paralysis have been identified.
Today in Research & Development...keeping you current
Receive free subspecialty "5-minute updates" via email
Bayer Team wins the “Deutscher Zukunftspreis” awarded by the German President
BayNews International, 12/03/09
GSK Update: GSKs Arepanrix H1N1 pandemic vaccine prequalified by the World Health Organization
GlaxoSmithKline, 12/02/09
Bayer Schering Pharma to collaborate with Micromet on novel approach to cancer therapy
BayNews International, 12/02/09